Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M118,204Revenue $M20,765Net Margin (%)28.0Altman Z-Score2.7
Enterprise Value $M120,163EPS $7.5Operating Margin %33.8Piotroski F-Score6
P/E(ttm)20.7Beneish M-Score-2.7Pre-tax Margin (%)31.3Higher ROA y-yN
Price/Book4.310-y EBITDA Growth Rate %11.4Quick Ratio5.1Cash flow > EarningsY
Price/Sales5.85-y EBITDA Growth Rate %10.6Current Ratio5.5Lower Leverage y-yY
Price/Free Cash Flow14.3y-y EBITDA Growth Rate %14.6ROA % (ttm)8.3Higher Current Ratio y-yY
Dividend Yield %1.9PEG1.9ROE % (ttm)22.5Less Shares Outstanding y-yY
Payout Ratio %37.0Shares Outstanding M758ROIC % (ttm)20.9Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNJoel Greenblatt 2015-06-30 Add0.19%$151.6 - $169.17
($160.19)
$ 155.89-3%Add 48.52%459,125
AMGNFirst Eagle Investment 2015-06-30 Reduce-0.02%$151.6 - $169.17
($160.19)
$ 155.89-3%Reduce 9.71%449,294
AMGNDodge & Cox 2015-06-30 Reduce$151.6 - $169.17
($160.19)
$ 155.89-3%Reduce 7.13%50,804
AMGNMario Gabelli 2015-06-30 Add$151.6 - $169.17
($160.19)
$ 155.89-3%Add 1.48%40,575
AMGNKen Fisher 2015-06-30 Reduce$151.6 - $169.17
($160.19)
$ 155.89-3%Reduce 0.97%155,101
AMGNJoel Greenblatt 2015-03-31 Add0.37%$150.01 - $170.1
($157.49)
$ 155.89-1%Add 2874.44%309,134
AMGNFirst Eagle Investment 2015-03-31 Reduce-0.06%$150.01 - $170.1
($157.49)
$ 155.89-1%Reduce 23.66%497,622
AMGNMario Gabelli 2015-03-31 Add$150.01 - $170.1
($157.49)
$ 155.89-1%Add 1.23%39,985
AMGNKen Fisher 2015-03-31 Add$150.01 - $170.1
($157.49)
$ 155.89-1%Add 1.41%156,623
AMGNDodge & Cox 2015-03-31 Reduce$150.01 - $170.1
($157.49)
$ 155.89-1%Reduce 17.65%54,704
AMGNVanguard Health Care Fund 2014-12-31 Reduce-0.51%$130.45 - $171.64
($155.84)
$ 155.890%Reduce 20.54%5,580,485
AMGNMario Gabelli 2014-12-31 Reduce-0.02%$130.45 - $171.64
($155.84)
$ 155.890%Reduce 34.11%39,500
AMGNJoel Greenblatt 2014-12-31 Add0.01%$130.45 - $171.64
($156.25)
$ 155.89-0%Add 285.93%10,393
AMGNVanguard Health Care Fund 2014-09-30 Reduce-0.32%$115.39 - $144.01
($130.57)
$ 155.8919%Reduce 12.75%7,022,755
AMGNFirst Eagle Investment 2014-09-30 Buy 0.25%$115.39 - $144.01
($130.57)
$ 155.8919%New holding714,178
AMGNKen Fisher 2014-09-30 Add0.02%$115.39 - $144.01
($130.57)
$ 155.8919%Add 83.59%156,629
AMGNJoel Greenblatt 2014-09-30 Reduce-0.01%$115.39 - $144.01
($130.57)
$ 155.8919%Reduce 72.90%2,693
AMGNRuane Cunniff 2014-09-30 Buy $115.39 - $144.01
($130.57)
$ 155.8919%New holding1,617
AMGNVanguard Health Care Fund 2014-06-30 Reduce-0.06%$110.29 - $126.07
($115.88)
$ 155.8935%Reduce 2.00%8,049,455
AMGNMario Gabelli 2014-06-30 Add0.02%$110.29 - $126.07
($115.72)
$ 155.8935%Add 85.28%60,335
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Hassan FredDirector 2015-08-19Buy3,010$166.63-6.45view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-13.59view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.06-0.74view
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.87-1.25view
Tross Stuart ASVP, Human Resources 2015-04-23Sell3,012$169.31-7.93view
Harper Sean EEVP, Research & Development 2015-04-22Sell28,000$171.58-9.14view
Tross Stuart ASVP, Human Resources 2015-03-03Sell4,415$157.74-1.17view
BALTIMORE DAVIDDirector 2015-03-02Sell3,647$158.76-1.81view
Bradway Robert AChairman, CEO and President 2015-02-11Sell22,000$152.692.1view
HERRINGER FRANK CDirector 2015-02-05Buy3,000$152.292.36view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

News about AMGN:

Articles On GuruFocus.com
The Best Companies of the Pharmaceuticals Industry – August 2015 Aug 18 2015 
Perrigo Company Is Strong But Overvalued Jul 15 2015 
Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 
PRIMECAP Sells Portions of Its Top Two Stakes May 27 2015 
Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
Amgen’s Cholesterol Fighting Drug Receives EU Approval May 26 2015 
Crouching Tigers, Hidden Assets – Smead Capital Management Apr 30 2015 
securities Apr 27 2015 
Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
Amgen Inc.’s First Quarter Earnings Preview – What Could Be In Store? Apr 20 2015 

More From Other Websites
​Amgen wins FDA approval for cholesterol drug Repatha Aug 28 2015
Gilead & Amgen Account for Nearly 75% of the Biotech Profit Pool Aug 28 2015
Amgen v. Regeneron: Everyone Wins? Aug 28 2015
Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S. Aug 28 2015
How Amgen Can Disrupt the Market for Cholesterol Drugs Aug 28 2015
Time to Buy Amgen After Newly Approved Drug? Aug 28 2015
Early movers: BIG, MYL, FCX, BGS, FB, ADSK & more Aug 28 2015
Amgen approved for pricey new drug Aug 28 2015
PRESS DIGEST- New York Times business news - August 28 Aug 28 2015
FDA Approves Amgen’s Cholesterol-Lowering Drug Repatha Aug 27 2015
The New Cholesterol Lowering Drugs Epitomize The Drug Pricing Battles Aug 27 2015
Amgen wins approval for second biotech cholesterol drug Aug 27 2015
Amgen wins approval for second biotech cholesterol drug Aug 27 2015
FDA approves Amgen cholesterol-lowering drug Repatha for some patients Aug 27 2015
Amgen's Repatha OK'd With Similar Label To Praluent Aug 27 2015
FDA approves Amgen's cholesterol-lowering drug Repatha Aug 27 2015
FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab) Aug 27 2015
5:52 pm Amgen confirms FDA approval of Repatha (evolocumab) Injection for the treatment of high... Aug 27 2015
FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab) Aug 27 2015
FDA approves Amgen's cholesterol drug Aug 27 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK